Folks, while the whole world have been distracted by the George Floyd protest, police brutality, Black Lives Matter, the real scam has been sped up and is coming into your body.
I wonder if people will still have energy to fight this real battle against forced vaccination after having been exhausted and divided by George Floyd protest and senseless riots.
From such angle, you can see clearly how people have been played spectacularly!
This is truly a war on humanity. All around the world, THEY , through the Power of the State, have murdered people young and old, blacks, whites, yellows, browns in hospitals, on the streets. Their thugs, their executioners, are not only just police force, but scientists, medical doctors, nurses! All is in front of your eyes! Yet, people have been channeled to hate, kill, and destroy each other life and property with all the nonsensical and stupid political correctness!
I have to make this short. because my vision has been worse (blurring). I need to take a break, folks.
Please, read the article below carefully and BETWEEN THE LINES … pay attention to their choice of words and jargon…then work out yourself.
Just remember my analogy: The China ChiCom is just a conductor, a true Maestro though, of this statist Covid-Grand-Symphony Orchestra. Those who composed this grand symphony are the ones we need to expose. No, not Bill Gates, Jeffery Epstein, George Soros etc…like politicians of the day, these billionaires may last longer but still are disposable. Don’t be distracted by their noises.
As always, the last word is yours.
Stay safe and be humane folks!
Can China win Covid-19 vaccine race with old school technology?
- Chinese teams are behind half of the world’s potential vaccines making fastest progress but their approach differs from the West.
- If testing hurdles can be overcome, inactivated vaccines may hold hope for beating coronavirus
Published: 6:59am, 18 Jun, 2020
China is leading the race to develop a Covid-19 vaccine and its scientists are largely pinning their hopes on a technology that has been used for decades.
Five out of 10 potential vaccines undergoing clinical trials have been developed by Chinese scientists, while a sixth is the result of a partnership between a Chinese company and a German biotech firm, according to the World Health Organisation.
But China is adopting a very different approach in its hunt for a vaccine against the disease caused by the new coronavirus. It is the only country pouring resources into the use of inactivated viruses, a technique used in vaccines against numerous diseases in the past – including hepatitis A, influenza and polio – but largely shunned in new vaccine development.
The technology is simple and involves growing a virus strain in the laboratory and then using heat or chemicals to destroy its ability to replicate. Once injected as a vaccine, the immune system recognises the antigens in the inactive virus and reacts by making antibodies. https://multimedia.scmp.com/2019/graphics/launchers/20200603.html
Of the five vaccine candidates undergoing clinical trials in China, all but one involve inactivated viruses. There are a further 126 potential vaccines in preclinical evaluation around the world and, again, only five of these are based on the decades-old technique. Two are being developed by Chinese companies, with scientists in Japan, Kazakhstan and France working on the remainder.Most Western scientists are turning to newer technologies, with many putting their energy into experimental nucleic acid vaccines based on genetically engineered virus DNA, despite there being – as yet – no licensed human vaccine using this technique. A high-profile example is US biotech firm Moderna’s mRNA vaccine, expected to enter its final phase of clinical trial in July, with 30,000 participants.
One reason developed countries have shown little interest in trialling inactivated vaccines is that immunity can be of limited duration, with more doses required over time. Another problem, according to scientists, is the higher risk of adverse reaction – known as an enhanced disease response – because the entire virus strain is used, which may contain harmful antigens. https://open.spotify.com/embed-podcast/episode/3lfpjfvqrVCEbvNGzVCzs4
Stanley Alan Plotkin, who invented the rubella vaccine and now advises WHO and pharmaceutical manufacturers, said there would need to be “lots of safety data and proof of efficacy” for any inactivated vaccine against Covid-19. “There are concerns about inducing disease enhancing responses and destruction of important epitopes [the parts of the antigen recognised by the immune system] on the virus.”
However, scientists generally agreed these were theoretical concerns at this stage because trials were required to find out exactly how animals and human bodies responded to a vaccine candidate.In separate reports, published in April and May respectively, researchers working on two inactivated vaccine candidates went to some length to address these concerns. The two teams – one a joint project between the Beijing Institute of Biological Products and state-owned Sinopharm, and the other from privately owned Sinovac Biotech – found no enhanced disease response in testing on rhesus macaques.
Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful
Earlier this week, developers of two potential inactivated vaccines, China National Biotec Group and Sinovac, announced their respective candidates had passed phase 1 and 2 of their clinical trials and were proceeding to the final phase.
While the findings from animal trials have yielded encouraging indicators, the risks of enhanced disease response cannot be ruled out until scientists get data from vaccinated people who have then been exposed to the disease.
Helen Petousis-Harris, associate professor of vaccinology at the University of Auckland, said there were pros and cons in the manufacturing of inactivated vaccines.
“One of the advantages to this technology is that it is well established and there are existing manufacturing facilities all over the world able to produce these sorts of vaccines,” she said, but the safety requirements were high, because of the need to grow live viruses before making them inactive. “Another disadvantage is that you have to grow a large amount of the virus,” she said.
With four candidate inactivated vaccines now in clinical trials, China is pouring money into upgrading and building high-security P3 facilities to prepare for the manufacture of inactivated vaccines. One advantage – highlighted in April by Wu Yuanbin, director general of the science ministry’s department of science and technology for social development – is that the technique is well established.
“The production technology is relatively mature. There are standards of quality control … and there are international standards for the safety and efficacy of the vaccines. These can help to speed up the use of inactivated vaccines,” he said.
But China is not focusing on inactivated vaccines alone. In February, Beijing mobilised scientific institutes and government agencies to explore vaccines via “five technical routes” – inactivated vaccine, adenovirus vector vaccine, recombinant protein vaccine, attenuated influenza virus vector vaccine and nucleic acid vaccine.
The Chinese government’s strategy is to allow several dozen institutes to compete and then pick the best and fastest for more state support. Not surprisingly, the four inactivated vaccine candidates are ahead in the race in terms of speed, along with an adenovirus vector vaccine, developed by China’s top military virologist Chen Wei, for which President Xi Jinping reportedly has high hopes.
The adenovirus family is a group of viruses responsible for the common cold. The genetically-engineered adenovirus type 5 vaccine, jointly developed by CanSino Biological and a team led by Chen, from the Academy of Military Sciences, is based on an Ebola vaccine which was previously developed by Chen but never mass-produced.
Adenovirus type 5 is used as a vector to express the Sars-CoV-2 spike protein which then induces an immunity response in humans. One concern about this approach is that, because the common virus has been circulating in numerous human populations, it could be knocked out by pre-existing immunity before triggering a response against the Covid-19 virus.
Chen’s team published a paper in British-based medical journal The Lancet in May which acknowledged the concerns about pre-existing immunity and said more trials were required.
Another vaccine candidate, developed by US billionaire scientist and businessman Patrick Soon-Shiong and chosen by Warp Speed – a US government vaccine programme – is also using the common adenovirus type 5 as a vector, although scientists in this project are altering the adenovirus to make it more difficult for pre-existing immunity to undermine its efficacy.
US scientist and billionaire Patrick Soon-Shiong has developed a potential Covid-19 vaccine based on a common adenovirus. Photo: TNSSeveral other front runners under development by Western scientists are also based on adenoviruses, including a potential vaccine by the University of Oxford and AstraZeneca, and another by US pharmaceutical giant Johnson & Johnson. Both use adenoviruses not present in the human population as vectors.
China plans to have one or more candidate vaccines ready for emergency use this autumn, but is facing a challenge in progressing clinical trials to phase 3, because of the country’s current low transmission rate. CanSino said earlier it planned to carry out phase 3 trials in Canada while Sinovac said it had reached an agreement to conduct phase 3 trials in Brazil.
Science and technology minister Wang Zhigang has said China will make any successful vaccines available as a public good for the world and scientists see no reason inactivated vaccines developed by the Chinese should not be licensed overseas, provided there is sufficient data to prove both safety and efficacy. https://multimedia.scmp.com/2019/graphics/launchers/20200506.html
“If inactivated vaccines are efficacious in field trials and there is no evidence of enhanced disease, then I would not foresee obstacles for licensure for use, provided they meet all the other (usual) conditions for licensure,” said Peter Smith, professor of tropical epidemiology at the London School of Hygiene & Tropical Medicine and a WHO adviser on vaccine development.
“In the present situation, even a vaccine with short-term efficacy would be preferable to not having a vaccine,” he added.
Tao Lina, a Shanghai-based vaccine expert, said China was pursuing all five technical routes because it did not want to put all its eggs in one basket. Pursuing a well-established technology like inactivated vaccines may increase the chance of success, he said.
“We were hit by the epidemic hardest a few months ago and we are eager to have a vaccine. Inactivated vaccine is a safe bet,” Tao said, adding that, because the technology was straightforward, if one inactivated vaccine was successful others developed using the same technique were likely to be successful too.
Petousis-Harris said it was important for scientists around the world to explore different options, though New Zealand – which only recently joined the vaccine race – would opt for newer technologies like protein and nucleic acid vaccines, instead of old technologies like inactivated vaccines.
“The important thing is to have all of these approaches in play for two reasons. One, because many will fail or have more limited effect, and two, because in order to produce enough vaccines for the global population we will want to be able to use as many manufacturing options as possible,” she said.
“Some vaccines may come sooner than others and better vaccines may take more time. It is important to cover as many possibilities as we can.”./.